SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $RHHBY–Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab) for the treatment of adult patients with primary membranous nephropathy (pMN) at risk of disease progression, to induce remission of proteinuria. Gazyva becomes the first and only therapy to receive FDA approval for this disease, having previously been granted Breakthrough Therapy D

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.